Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jamie B Spangler

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
Biorxiv : the Preprint Server for Biology|May 19, 2023
Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activityElissa K Leonard, Jakub Tomala, Joseph R Gould, et al.
Cell Reports|August 20, 2023
IL-2 can signal via chemokine receptors to promote regulatory T cells' suppressive functionHao Sun, Ho-Sup Lee, Sarah Hyun-Ji Kim, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2025
Transient Poly(ADP-Ribose) Triggers FUS Condensation Hysteresis via a Prion-Like MechanismHongrui Liu, Yuxuan Cai, Leilei Shi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 11, 2021
Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeuticsDhiraj Kumar, Akhilesh Mishra, Ala Lisok, et al.
Cell Chemical Biology|April 28, 2024
Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1Seth D Ludwig, Bunyarit Meksiriporn, Jiacheng Tan, et al.
Cell Chemical Biology|March 28, 2024
Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1Seth D Ludwig, Bunyarit Meksiriporn, Jiacheng Tan, et al.
Immunity|May 21, 2015
Interleukin-2 activity can be fine tuned with engineered receptor signaling clampsSuman Mitra, Aaron M Ring, Shoba Amarnath, et al.
Nature Communications|October 14, 2022
Nanoparticle-based modulation of CD4<sup>+</sup> T cell effector and helper functions enhances adoptive immunotherapyAriel Isser, Aliyah B Silver, Hawley C Pruitt, et al.
Nature Reviews Bioengineering|April 17, 2023
Engineering cytokine therapeuticsJeroen Deckers, Tom Anbergen, Ayla M Hokke, et al.
Nature Biotechnology|November 1, 2022
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapyAlfredo Quijano-Rubio, Aladdin M Bhuiyan, Huilin Yang, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Biorxiv : the Preprint Server for Biology|May 19, 2023
Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activityElissa K Leonard, Jakub Tomala, Joseph R Gould, et al.
Cell Reports|August 20, 2023
IL-2 can signal via chemokine receptors to promote regulatory T cells' suppressive functionHao Sun, Ho-Sup Lee, Sarah Hyun-Ji Kim, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2025
Transient Poly(ADP-Ribose) Triggers FUS Condensation Hysteresis via a Prion-Like MechanismHongrui Liu, Yuxuan Cai, Leilei Shi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 11, 2021
Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeuticsDhiraj Kumar, Akhilesh Mishra, Ala Lisok, et al.
Cell Chemical Biology|April 28, 2024
Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1Seth D Ludwig, Bunyarit Meksiriporn, Jiacheng Tan, et al.
Cell Chemical Biology|March 28, 2024
Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1Seth D Ludwig, Bunyarit Meksiriporn, Jiacheng Tan, et al.
Immunity|May 21, 2015
Interleukin-2 activity can be fine tuned with engineered receptor signaling clampsSuman Mitra, Aaron M Ring, Shoba Amarnath, et al.
Nature Communications|October 14, 2022
Nanoparticle-based modulation of CD4<sup>+</sup> T cell effector and helper functions enhances adoptive immunotherapyAriel Isser, Aliyah B Silver, Hawley C Pruitt, et al.
Nature Reviews Bioengineering|April 17, 2023
Engineering cytokine therapeuticsJeroen Deckers, Tom Anbergen, Ayla M Hokke, et al.
Nature Biotechnology|November 1, 2022
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapyAlfredo Quijano-Rubio, Aladdin M Bhuiyan, Huilin Yang, et al.
Pageof 9